- AbbVie’s Humira was the world’s best-selling pharmaceutical product in 2020, but is facing a loss of exclusivity and increasingly intense biosimilars competition.
- In preparation for Humira’s sales decline, the company has lined up Rinvoq and Skyrizi in its slate.
- However, the industry's and the Street’s forecasts are not anywhere near the company’s internal estimates.
- Investors may have to brace themselves for potential value compressions, especially when the chart shows that a lot of optimism has already been priced in.
For further details see:
AbbVie Is Going To Find It Tough Moving On From Humira